Astellas Lifts Profit Forecast on Lower R&D Costs, Land Sale

Astellas Pharma Inc. (4503), Japan’s third- largest drugmaker, increased its full-year profit forecast by 4.9 percent because of lower research and development costs and a gain from the sale of land.

Net income will jump 26 percent to 85 billion yen ($1.1 billion) in the year ending March 2012. That’s instead of the 81 billion yen previously forecast, Tokyo-based Astellas said in a statement today. Profit in the six months ended Sept. 30 increased 17 percent, it said.

R&D costs may be 6 billion yen less than previously estimated, and sales and administrative costs may also be lower than predicted earlier, the company said. The company booked a 10 billion yen gain from a sale of land in Tokyo for the six months ended Sept. 30, it said.

Net income rose to 51.3 billion yen in the fiscal first half, or 111 yen a share, from 43.9 billion yen, or 95 yen, a year earlier, Astellas said. It reported preliminary earnings on Oct. 28.

Astellas fell 1 percent to 2,858 yen as of the 3 p.m. close in Tokyo trading, while Japan’s benchmark Topix index declined 1.3 percent.

To contact the reporter on this story: Kanoko Matsuyama in Tokyo at kmatsuyama2@bloomberg.net

To contact the editor responsible for this story: Jason Gale at j.gale@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.